MGO One Seven LLC Grows Position in Zoetis Inc. (NYSE:ZTS)

MGO One Seven LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 64.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,401 shares of the company’s stock after purchasing an additional 4,469 shares during the quarter. MGO One Seven LLC’s holdings in Zoetis were worth $1,858,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZTS. Norges Bank acquired a new stake in Zoetis during the fourth quarter valued at $824,321,000. Wellington Management Group LLP boosted its stake in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Zoetis during the 4th quarter worth about $196,651,000. Polen Capital Management LLC grew its position in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Finally, Capital Research Global Investors purchased a new position in shares of Zoetis in the 4th quarter valued at about $178,688,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS opened at $152.52 on Friday. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market capitalization of $68.05 billion, a PE ratio of 27.88, a PEG ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm’s 50-day moving average price is $158.96 and its 200 day moving average price is $168.86.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

A number of equities analysts have issued reports on ZTS shares. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $214.40.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last quarter. Company insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.